uniQure (NASDAQ:QURE) CEO Matthew Kapusta Sells 41,671 Shares

uniQure N.V. (NASDAQ:QURE) CEO Matthew Kapusta sold 41,671 shares of the firm’s stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $50.00, for a total transaction of $2,083,550.00. Following the completion of the transaction, the chief executive officer directly owned 521,795 shares of the company’s stock, valued at approximately $26,089,750. This trade represents a 7.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

uniQure Stock Performance

NASDAQ:QURE opened at $44.39 on Tuesday. The business’s fifty day moving average is $25.30 and its 200 day moving average is $22.30. uniQure N.V. has a 52-week low of $8.73 and a 52-week high of $71.50. The firm has a market cap of $2.80 billion, a price-to-earnings ratio of -12.76 and a beta of 0.98. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.40 and a current ratio of 10.40.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The company had revenue of $3.56 million during the quarter, compared to analyst estimates of $5.21 million. Research analysts predict that uniQure N.V. will post -3.64 EPS for the current year.

Hedge Funds Weigh In On uniQure

A number of institutional investors have recently added to or reduced their stakes in the company. Avoro Capital Advisors LLC lifted its position in uniQure by 38.4% during the fourth quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock valued at $147,170,000 after buying an additional 1,705,556 shares during the period. Aberdeen Group plc increased its stake in shares of uniQure by 25.1% in the 4th quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock worth $88,030,000 after acquiring an additional 738,897 shares in the last quarter. State Street Corp increased its stake in shares of uniQure by 123.8% in the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock worth $77,319,000 after acquiring an additional 1,787,033 shares in the last quarter. JPMorgan Chase & Co. lifted its position in uniQure by 155.3% during the 4th quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock valued at $70,226,000 after acquiring an additional 1,785,275 shares during the period. Finally, Orbimed Advisors LLC boosted its stake in uniQure by 189.7% during the first quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock worth $34,926,000 after acquiring an additional 1,398,749 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.

Key uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: uniQure reported initial AMT-260 data in temporal lobe epilepsy showing meaningful seizure reductions in early patients, with no treatment-related serious adverse events, which supports the company’s gene-therapy pipeline. Article Title
• Positive Sentiment: Early trial updates also highlighted seizure reductions of 79% to 100% in three patients, reinforcing investor optimism around AMT-260’s potential. Article Title
• Neutral Sentiment: The company also announced preliminary data from the first cohort in its Phase I/IIa AMT-260 clinical trial, a routine but important catalyst for a development-stage biotech. Article Title
• Negative Sentiment: uniQure announced a $150 million underwritten public offering, with an additional $22.5 million greenshoe option, which could dilute existing shareholders even if it strengthens the balance sheet. Article Title
• Negative Sentiment: Recent insider selling by the CEO and two directors may also weigh on sentiment, even though the transactions were made under pre-arranged 10b5-1 plans. Article Title

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on QURE. Barclays upgraded shares of uniQure from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $25.00 to $65.00 in a research report on Thursday, June 18th. Cantor Fitzgerald upgraded shares of uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 target price on the stock in a report on Wednesday, June 17th. HC Wainwright reaffirmed a “buy” rating on shares of uniQure in a research note on Thursday. Wells Fargo & Company upgraded uniQure from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $15.00 to $60.00 in a report on Monday, March 9th. Finally, Royal Bank Of Canada upped their price target on uniQure from $35.00 to $65.00 and gave the company an “outperform” rating in a research report on Thursday. Twelve research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $58.92.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.